EPHA2 and glioblastoma: These well-characterized findings make EphA2 a candidate for efficacious targeted therapy for GBM: in fact, Affinito et al. very recently selected and characterized 2′-fluoropyrimidine-containing RNA aptamers (40L and its truncated form, A40s).